We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

16 hedge funds and large institutions have $5.29M invested in AIM ImmunoTech in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

145% more capital invested

Capital invested by funds: $2.15M → $5.29M (+$3.13M)

33% more funds holding

Funds holding: 12 → 16 (+4)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$656K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$402K
3
Citadel Advisors
Citadel Advisors
Florida
+$106K
4
Millennium Management
Millennium Management
New York
+$106K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$84.6K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$139K
2
Renaissance Technologies
Renaissance Technologies
New York
-$30K
3
Goldman Sachs
Goldman Sachs
New York
-$6K

AIM Hedge Fund Activity: Q1 2014 in Review

16 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2014, worth a combined $5.29M — up 145% from $2.15M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AIM positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock Institutional Trust, adding an estimated $656K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $139K sold.

  • 16 institutional investors held AIM ImmunoTech (AIM) as of Q1 2014, up from 12 in Q4 2013.
  • Funds reported $5.29M of AIM ImmunoTech stock for Q1 2014, up 145% quarter-over-quarter.
  • 6 funds opened new AIM ImmunoTech positions in Q1 2014 and 2 closed out, a net change of +4 holders.
  • The largest AIM ImmunoTech buyer in Q1 2014 was BlackRock Institutional Trust, an estimated $656K added.
  • The largest AIM ImmunoTech seller in Q1 2014 was Jacobs Levy Equity Management, an estimated $139K sold.

Based on aggregated 13F filings for Q1 2014.